T3SS Inhibitors Block Effector Secretion to Combat Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections caused by Pseudomonas aeruginosa and other Gram-negative pathogens are inadequate due to high mortality rates, relapse, and the emergence of drug-resistant strains, highlighting the need for new therapeutic agents that target the bacterial type III secretion system (T3SS).
Innovation Solution
Development of specific bacterial T3SS inhibitor compounds, identified through a cell-based bioluminescent reporter assay, which inhibit the T3SS-mediated secretion and translocation of effector toxins from bacterial cells, including Pseudomonas, Yersinia, and Chlamydia species, using compounds such as phenoxyacetamide derivatives like MBX 1641 and MBX 1684.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bacteriostatic and bactericidal antibiotics are used to treat P. aeruginosa infections, then bacterial growth is inhibited or killed, but treatment fails due to drug-resistant strains and high mortality rates
Solution Approach 1:
The patent extracts and targets the specific virulence mechanism (T3SS) rather than attempting to kill the entire bacterium. By using inhibitors like MBX 1641 that specifically block the T3SS secretion system, the treatment disables the bacteria's ability to cause harm without necessarily killing the bacterial cells, thereby avoiding selection for drug-resistant strains while still achieving therapeutic effectiveness
Solution Approach 2:
The invention applies local quality by targeting a specific functional component (the T3SS secretion apparatus) rather than applying broad-spectrum antibiotics that affect all bacterial processes. The inhibitors specifically interfere with the secretion of effector proteins through the T3SS, leaving other bacterial functions intact, which reduces selective pressure for resistance development while maintaining treatment reliability
2Object-affected harmful factors
If T3SS inhibitors are developed to target virulence factors, then bacterial virulence is reduced, but new therapeutic agents with high specificity and low cytotoxicity are needed
Solution Approach 1:
The patent employs small molecule inhibitors (such as MBX 1641 and its derivatives) as intermediary compounds that specifically bind to and inhibit the T3SS secretion machinery. These intermediary agents bridge the gap between the host's immune system and the bacterial virulence factors, blocking the secretion of effector proteins without directly interacting with the bacteria or host cells in a non-specific manner, thereby achieving high specificity with low cytotoxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit T3SS activity with high specificity and low cytotoxicity, demonstrating potential as adjunctive therapies to combat bacterial infections by blocking virulence factor secretion and translocation, thereby enhancing the host's immune response to clear infections.
Implementation Method 1
a cell-based bioluminescent reporter assay was developed and employed as a high throughput primary screen to identify putative inhibitors of the P. aeruginosa T3SS
Data Source
AI summary
Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.